China
Africa
Explore chapters and articles related to this topic
General surgery
Published in Kaji Sritharan, Jonathan Rohrer, Alexandra C Rankin, Sachi Sivananthan, Essential Notes for Medical and Surgical Finals, 2021
Kaji Sritharan, Jonathan Rohrer, Alexandra C Rankin, Sachi Sivananthan
Acute diverticulitis: inflammation in one or more diverticula. Clinical features: LIF (or less commonly RIF) pain, anorexia, nausea and vomiting +/- change in bowel habit +/- urinary symptoms (due to proximity of the sigmoid colon to the bladder); may have palpable mass on abdominal exam; DRE – mass/tenderness
In Vitro Tests for Adverse Drug Reactions Based on Cytokine Release
Published in Kirsti Kauppinen, Kristiina Alanko, Matti Hannuksela, Howard Maibach, Skin Reactions to Drugs, 2020
LIF is a T-cell-derived lymphokine, initially defined by its ability to inhibit the random migration of neutrophils.5 It has been shown recently that LIF, a correlate of CMI, is a potentially important activator of neutrophil function.61 LIF is assayed frequently in clinical studies in the leukocyte migration test (LMT).
Immunomodulation of Cytokines and T Cells by Biologicals in Rheumatoid Arthritis
Published in Thomas F. Kresina, Immune Modulating Agents, 2020
Ravinder N. Maini, Marc Feldmann
A cytokine produced in abundance is IL-6 [21], which circulates in blood and appears to exert a major effect on hepatocytes with the production of C-reactive protein, serum amyloid A protein, and other acute phase proteins characteristically found in RA blood. Leukemia inhibitory factor (LIF) is also produced to the joint and may be involved in inducing these proteins, via the gp 130 receptor chain, shared with the IL-6 receptor.
Leukemia Inhibitory Factor Impairs the Function of Peripheral γδT Cells in Patients with Colorectal Cancer
Published in Immunological Investigations, 2023
Xueyan Xi, Ting Deng, Fen Qiu, Yunhe Zhu, Yumei Li, Gang Li, Yang Guo, Boyu Du
As a member of the IL-6 cytokine family, leukemia inhibitory factor (LIF) is highly expressed in cancer tissues, and its serum level is increased in several solid tumor diseases (Bian et al. 2021; Nicola and Babon 2015; Shi et al. 2019; Viswanadhapalli et al. 2021; Yu et al. 2014). The effects of LIF are mainly exerted by the combination of LIF and its receptor complex, which is composed of two subunits: LIF receptor (LIFR) and gp130. LIFR determines the specificity of the receptor complex (Nicola and Babon 2015; Viswanadhapalli et al. 2021). Recent studies have revealed that LIF contributes to the progression of certain cancers, and its expression is correlated with poor prognosis in various cancer diseases (Pascual-Garcia et al. 2019; Shi et al. 2019; Viswanadhapalli et al. 2021). LIF can facilitate the formation of an immunosuppressive tumor microenvironment via the regulation of tumor-associated macrophage generation in ovarian cancer (Duluc et al. 2007). LIF has also been observed to regulate protumoral cytokine expression in tumor-associated macrophages and CD8+ T cell tumor infiltration (Pascual-Garcia et al. 2019). As a result, LIF is considered a promising drug target, and its blocking antibody (MSC-1) is currently being evaluated in clinical trials (ClinicalTrials.gov Identifier: NCT03490669). However, whether LIF regulates the cytotoxic function of peripheral γδT cells is not fully known.
Protection of leukemia inhibitory factor against high-glucose-induced human retinal endothelial cell dysfunction
Published in Archives of Physiology and Biochemistry, 2023
Lei Wang, Qiong Wu, Rui Qi Wang, Run Ze Wang, Jianwen Wang
Previous reports have shown that multiple cytokines and chemokines play vital roles in DR, suggesting inflammation is a critical factor that is responsible for DR-related changes (Banerjee et al.2007, Oh et al.2010). Compared with non-diabetic individuals, DR patients have a high level of inflammatory activity from both clinical and laboratory results. In our study, we simulated diabetic retinopathy with HRECs and studied the effect of LIF on the expression of inflammatory factors in HRECs induced by high glucose. The results showed that LIF could down-regulate the expression of inflammatory factors and inhibit the continuous occurrence of inflammatory reactions in HREC cell models. Besides, LIF can increase cell viability and inhibit apoptosis. Therefore, inhibiting inflammatory response may be a key strategy in the treatment of diabetic retinopathy.
Leukemia inhibitory factor (LIF) modulates the development of dendritic cells in a dual manner
Published in Immunopharmacology and Immunotoxicology, 2019
Atefeh Yaftiyan, Maryam Eskandarian, Amir Hossein Jahangiri, Nazanin Atieh Kazemi Sefat, Seyed Mohammad Moazzeni
Leukemia inhibitory factor (LIF) is a highly glycosylated pleiotropic member of interleukin-6 (IL-6) cytokine family, which primarily acts upon binding to LIF receptor (LIFR) and gp130 (IL-6 family shared receptor subunit) heterodimer [10]. Functional LIFRs are detected on a number of different cells including myeloid cells, T lymphocytes, DCs, and hepatocytes [11,12]. Many studies have reported that LIF is involved in a broad and diverse range of actions in endocrine, neural, hepatic, stromal, muscular, and renal systems [13]. Independently of these capabilities, substantial stack of evidence suggests that the cytokine is directly linked to several immunological events [11,14,15]. It appears that LIF is a key stimulator for the generation and progression of tumors, and increased serum levels of LIF does seem to correlate with tumor recurrence and metastasis [16,17].